These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 25059099)

  • 1. Updated NICE guideline: management of atrial fibrillation (2014).
    Senoo K; Lau YC; Lip GY
    Expert Rev Cardiovasc Ther; 2014 Sep; 12(9):1037-40. PubMed ID: 25059099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation.
    Garcia DA
    Thromb Res; 2012 Jan; 129(1):9-16. PubMed ID: 22018997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey.
    Lip GY; Bongiorni MG; Dobreanu D; Lewalter T; Hastrup Svendsen J; Blomström-Lundqvist C;
    Europace; 2013 Oct; 15(10):1526-32. PubMed ID: 24072770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalizing oral anticoagulant treatment in patients with atrial fibrillation.
    Capranzano P; Miccichè E; D'Urso L; Privitera F; Tamburino C
    Expert Rev Cardiovasc Ther; 2013 Aug; 11(8):959-73. PubMed ID: 23957907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of challenges in optimizing oral anticoagulation therapy for stroke prevention in atrial fibrillation.
    Fernandez MM; von Schéele B; Hogue S; Kwong WJ
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):87-102. PubMed ID: 23572283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention.
    Poli D; Antonucci E; Grifoni E; Abbate R; Gensini GF; Prisco D
    Thromb Haemost; 2009 Feb; 101(2):367-72. PubMed ID: 19190823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target-specific oral anticoagulants for stroke prevention in patients with atrial fibrillation: real-world considerations.
    Rosenberg DJ; Ansell J
    Hosp Pract (1995); 2012 Aug; 40(3):50-7. PubMed ID: 23086094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.
    Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Ioachim PM; Tica O; Boriani G; Cimaglia P; Diemberger I; Hellum CF; Mortensen B; Maggioni AP
    Am J Med; 2014 Jun; 127(6):519-29.e1. PubMed ID: 24486284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atrial fibrillation.
    Lip GY; Tse HF; Lane DA
    Lancet; 2012 Feb; 379(9816):648-61. PubMed ID: 22166900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation.
    Myat A; Ahmad Y; Haldar S; Tantry US; Redwood SR; Gurbel PA; Lip GY
    Expert Rev Cardiovasc Ther; 2013 Aug; 11(8):1029-49. PubMed ID: 23984927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anticoagulation in atrial fibrillation. Strategies in special situations].
    Volkmann H; Walter M; Walter C; Vetter S
    Clin Res Cardiol Suppl; 2011 May; 6():58-65. PubMed ID: 22528179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation.
    Overvad TF; Larsen TB; Albertsen IE; Rasmussen LH; Lip GY
    Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1619-29. PubMed ID: 24215192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stroke prevention in atrial fibrillation.
    Piccini JP; Wallace TW; Patel MR; Becker RC
    Cardiovasc Drugs Ther; 2011 Dec; 25(6):561-70. PubMed ID: 21927837
    [No Abstract]   [Full Text] [Related]  

  • 15. Warfarin in non-valvular atrial fibrillation.
    Dalby AJ; Wessels P; Opie LH
    S Afr Med J; 2013 Oct; 103(12):901-4. PubMed ID: 24300625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stroke prevention in atrial fibrillation: an update on current management strategies.
    Hall T; Stanton T; Wang WY; Ng AC
    Panminerva Med; 2013 Mar; 55(1):43-58. PubMed ID: 23474663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing an Atrial Fibrillation Guideline Support Tool (AFGuST) for shared decision making.
    Eckman MH; Wise RE; Naylor K; Arduser L; Lip GY; Kissela B; Flaherty M; Kleindorfer D; Khan F; Schauer DP; Kues J; Costea A
    Curr Med Res Opin; 2015 Apr; 31(4):603-14. PubMed ID: 25690491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation.
    Hylek EM
    Thromb Haemost; 2008 Jul; 100(1):16-7. PubMed ID: 18612532
    [No Abstract]   [Full Text] [Related]  

  • 19. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance.
    Ahmad Y; Lip GY
    Heart; 2012 Oct; 98(19):1404-6. PubMed ID: 22698856
    [No Abstract]   [Full Text] [Related]  

  • 20. New Oral Anticoagulants: Need and Challenges in a Developing Country.
    Khan M; Wasay M
    J Coll Physicians Surg Pak; 2016 Jul; 26(7):551-2. PubMed ID: 27504541
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.